@article{049c4944644b4b15a6c382f646ce01e9,
title = "Cross-sectional and longitudinal atrophy is preferentially associated with tau rather than amyloid β positron emission tomography pathology",
abstract = "Introduction: Structural magnetic resonance imaging is a marker of gray matter health and decline that is sensitive to impaired cognition and Alzheimer's disease pathology. Prior work has shown that both amyloid β (Aβ) and tau biomarkers are related to cortical thinning, but it is unclear what unique influences they have on the brain. Methods: Aβ pathology was measured with [18F] AV-45 (florbetapir) positron emission tomography (PET) and tau was assessed with [18F] AV-1451 (flortaucipir) PET in a population of 178 older adults, of which 123 had longitudinal magnetic resonance imaging assessments (average of 5.7 years) that preceded the PET acquisitions. Results: In cross-sectional analyses, greater tau PET pathology was associated with thinner cortices. When examined independently in longitudinal models, both Aβ and tau were associated with greater antecedent loss of gray matter. However, when examined in a combined model, levels of tau, but not Aβ, were still highly related to change in cortical thickness. Discussion: Measures of tau PET are strongly related to gray matter atrophy and likely mediate relationships between Aβ and gray matter.",
keywords = "Amyloid, Atrophy, MRI, PET, Positron emission tomography, Tau, Thickness",
author = "Gordon, {Brian A.} and Austin McCullough and Shruti Mishra and Blazey, {Tyler M.} and Yi Su and John Christensen and Aylin Dincer and Kelley Jackson and Hornbeck, {Russ C.} and Morris, {John C.} and Ances, {Beau M.} and Benzinger, {Tammie L.S.}",
note = "Funding Information: Financial support was provided by NIH grants P01 AG003991, P50 AG005681, P01 AG026276, R01 AG043434, P30 NS098577, 1S10RR022984-01A1, 1S10OD018091, R01 EB009352, and UL1TR000448, as well as the Foundation of the American Society of Neuroradiology Research Scientist Award, gifts from the Charles and Joanne Knight Alzheimer Disease Research Center Support Fund, the David and Betty Farrell Medical Research Fund, the Daniel J Brennan Alzheimer Research Fund, the Thomas E. Brew Foundation Fund, the Barnes-Jewish Hospital Foundation, and the Fred Simmons and Olga Mohan Alzheimer Research Support Fund. Computations were performed using the Washington University Center for High Performance Computing. Avid Radiopharmaceuticals provided precursor materials and technology transfer for the synthesis of AV-1451, provided doses of AV-45, and provided funding to support the AV-45 scans as part of the NIH funded study, P01 AG003991. Publisher Copyright: {\textcopyright} 2018 The Authors",
year = "2018",
doi = "10.1016/j.dadm.2018.02.003",
language = "English",
volume = "10",
pages = "245--252",
journal = "Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring",
issn = "2352-8729",
}